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Abstract: Background: Following percutaneous coronary intervention, combined antiplatelet therapy is necessary. Platelet function testing (PFT) has
prognostic value and may be applied in the risk assessment of acute coronary syndrome. In case of combined antiplatelet therapy, PFT may require
special laboratory methods, as different antiplatelet agents may inﬂuence test results. Materials and methods: Platelet functions were measured in stent
thrombosis-segment elevation myocardial infarction patients receiving aspirin, clopidogrel, and tiroﬁban. The ﬁrst sampling was obtained immediately
after the termination of administration of tiroﬁban. The second sample was drawn at a randomly assigned time between 1 and 6 h. The third sampling
was done after a minimum of 24 h of tiroﬁban cessation. Adenosine diphosphate (ADP)- and thrombin receptor-activating peptide (TRAP)-induced
aggregations were measured. Results: Thirty-seven patients were included. Both TRAP- and ADP-induced aggregation values were signiﬁcantly lower
immediately after tiroﬁban termination, than after 24 h [TRAP: 26.41± 25.00 units (U) vs. 109.86± 23.69 U, p< 0.0001; ADP: 17.43± 10.10 U vs.
43.92± 23.35 U, p≤ 0.0001]. Elimination half-life of tiroﬁban and clopidogrel were 1.34± 0.49 and 1.269± 0.78, respectively. Conclusion: ADP-
induced residual platelet reactivity is signiﬁcantly inﬂuenced by the presence of concurrent glycoprotein IIb/IIIa inhibitor. In patients receiving
combined antiplatelet treatment, ADP-receptor-speciﬁc efﬁciency measurements are valid only after total elimination of GPIIb/IIIa inhibitors.
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Introduction
Cardiovascular diseases are considered as the leading
cause of death in developed countries. Percutaneous
coronary intervention (PCI) and the application of stents
resulted in substantial breakthrough in the treatment of
coronary heart disease, especially in patients with acute
coronary syndromes (ACSs). Because of the prothrom-
botic effect of the procedure and the underlying disease,
patients undergoing PCI and stent implantation have a
high risk for developing stent thrombosis (ST). Conse-
quently, an intensiﬁed combined antiplatelet therapy is
required at the time of the PCI that is tapered gradually
afterward [1, 2]. In addition to aspirin, adenosine
diphosphate (ADP) P2Y12 receptor blockers and platelet
glycoprotein (GP) IIb/IIIa (also known as integrin
αIIbβ3) inhibitors may be a part of these combinations.
As for ADP blockers, newer generation agents such as
prasugrel and ticagrelor are the ﬁrst choices of treatment
in patients with ACSs, as they provide more active and
consistent platelet inhibition. However, because of the
ﬁnancial and regulatory reasons, the availability of these
drugs is not optimal, thus the earlier generation ADP
blocker clopidogrel is still frequently used [3]. Clopido-
grel is a prodrug with variable action. In cases with
high ischemic risk, measurement of the residual ADP
reactivity may be considered. Although current guidelines
discourage the routine testing of patients after stent
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implantation, platelet function testing (PFT) has a clear
prognostic value and may be applied in the risk assessment
of ACS cases [1, 4]. Furthermore, in Hungary, prasugrel is
only reimbursed at the level of 70% in ACS patients with
diabetes and with veriﬁed impaired response to clopido-
grel. GPIIb/IIIa receptor antagonists, including tiroﬁban,
provide an immediate, very intensive inhibition of platelet
aggregation, but being parenteral agents, they are used
only temporarily in cases with high thrombotic burden and
thrombotic risk. The combined use of antiplatelet agents
may expose special requirements for laboratory testing, as
antiplatelet agents may inﬂuence the test results despite
their different mechanisms of action.
We aimed to investigate the effect of combined treat-
ment with ADP receptor blockers and GPIIb/IIIa
inhibitor tiroﬁban on ADP-receptor-speciﬁc platelet
function tested by Multiplate impedance aggregometry
in patients with ST-segment elevation myocardial infarc-
tion (STEMI) undergoing PCI.
Materials and Methods
Patients
We recruited ACS patients with STEMI admitted for
primary angioplasty in whom coronary intervention with
stent implantation was performed and tiroﬁban treatment
was initiated. Exclusion criteria were age over 75 years,
chronic treatment with thienopyridines, loading dose of
clopidogrel lower than 600 mg prior to PCI, concomitant
oral anticoagulant therapy, history of stroke or transient
ischemic attack, intolerance or allergy to clopidogrel/
aspirin, known bleeding disorders, and low platelet count
(<100 × 109/l). All patients received 600 mg of clopido-
grel and 300 mg of aspirin at the ﬁrst medical contact
when diagnosis of STEMI was established. Coronary
interventions were performed immediately after coronary
angiography revealing signiﬁcant coronary stenosis feasi-
ble for stent implantation. An intravenous bolus of
25 μg/kg of tiroﬁban was administered for all PCI
patients according to the operator’s decision, in case of
total thrombotic occlusion of a main coronary and/or
signiﬁcant thrombus burden. After PCI, tiroﬁban was
continued at a rate of 0.55 μg/kg/min maintenance dose
for 6 h. From the ﬁrst day after PCI, 100 mg of aspirin
was co-administered with 75 mg of clopidogrel in all
patients. The study protocol was approved by the regional
ethics committee (Approval no.: 3551) and patients gave
written consent for participation.
Blood sampling and aggregometry
Three milliliters of blood were drawn from each patient
from a peripheral vein into hirudin-coated vacuum tubes
(Becton and Dickinson, Munich, Germany). The ﬁrst
sampling and measurement were done immediately after
the termination of administration of GPIIb/IIIa inhibi-
tor tiroﬁban (Sample A), while a second sample was
drawn at a randomly assigned time between 1 and 6 h
(Sample B) and a third sample after a minimum of 24 h of
tiroﬁban cessation (Sample C). Multiple electrode aggre-
gometry (Multiplate, Roche Diagnostics GmbH,
Mannheim, Germany) was used for platelet function
assessments [5]. From each patient’s sample, 300 μl of
whole blood was stirred at 37 °C between two platinum
wire electrodes, set at a ﬁxed distance. We aimed to
measure the efﬁciency of clopidogrel and tiroﬁban. For
measuring clopidogrel efﬁcacy, ADP (0.2 mM, Roche)
was used as agonist agent. Efﬁciency of tiroﬁban was
determined indirectly, as the overall platelet function
independent from ADP reactivity. Thrombin receptor-
activating peptide (TRAP; 0.2 mM, Roche) was admin-
istered as the agonist agent in the determination of overall
platelet reactivity. The platelet aggregation was measured
automatically by Multiplate device, calculating the area
under the curve from the function of impedance to time.
Statistical analysis
Continuous variables are presented as means± SD.
Categorical variables are expressed as frequencies and
percentages. Data were analyzed according to their nor-
mal distribution on the Kolmogorov–Smirnov goodness-
of-ﬁt test. Paired t-tests were used for the comparison of
normally distributed continuous variables in the same
group between time points. Non-normally distributed
paired variables were compared using the Wilcoxon
matched pairs test. Hyperbolic curve ﬁttings to platelet
reactivity to time were prepared assuming single ligand–
receptor interaction. A p value <0.05 was considered
statistically signiﬁcant in all analyses. Statistical analyses
were performed with GraphPad InStat 3 version and
GraphPad Prism 6 version statistical packages (GraphPad
Software, San Diego, CA, USA).
The authors of this manuscript have certiﬁed that they
comply with the principles of ethical publishing [6].
Results
Patient characteristics
Between January 1, 2013 and December 31, 2013, a total
of 1,252 patients with ACS were admitted to the Heart
Institute at the University of Pécs for urgent coronary
angiography. Subsequent to coronary angiography, 632
patients underwent PCI with successful stenting. Thirty-
seven patients met the inclusion criteria and were
included in this study. Table I shows the baseline clinical
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characteristics of the recruited patients and data regarding
therapy.
Platelet aggregation proﬁles
Both TRAP- and ADP-induced aggregation values were
signiﬁcantly lower in samples obtained immediately after
the termination of tiroﬁban (Sample A), than in the
samples after 24 h (Sample C) [TRAP: 26.41± 25.00 units
(U) vs. 109.86± 23.69 U, p< 0.0001; ADP: 17.43±
10.10 U vs. 43.92± 23.35 U, p≤ 0.0001] (Fig. 1).
Residual platelet reactivity was demonstrated depending
on the time after the termination of tiroﬁban, and
performing curve ﬁttings, Kd values were determined: in
case of TRAP and ADP induction, these estimates were
1.34± 0.49 (95% CI: 0.35–2.32; Bmax = 112.5± 8.93)
and 1.269 ± 0.78 (Bmax = 51.15 ± 6.67), respectively
(Fig. 2).
Discussion
This study found that ADP-induced platelet reactivity
values, detected by Multiplate electrode aggregometry
may be inﬂuenced by tiroﬁban action, resulting in lower
values of ADP-induced residual platelet reactivity. Con-
sequently, this interaction may conceal the real residual
ADP reactivity, thus ADP receptor-speciﬁc efﬁciency
measurements are only possible after the total elimination
of GPIIb/IIIa inhibitor tiroﬁban.
Current recommendations based on 2014 European
Society of Cardiology/European Association for Cardio-
Thoracic Surgery (ESC/EACTS) Guidelines on myocar-
dial revascularization only support the use of GPIIb/IIIa
inhibitors in a smaller group of patients with myocardial
infarction (MI), as an adjunctive bail-out medication.
Despite the decreasing use of GPIIb/IIIa inhibitors
and – as our study shows – its inﬂuence on the measure-
ments of the blockage efﬁciency of ADP receptors, it is
important to note GPIIb/IIIa inhibitors’ beneﬁcial con-
tribution to the treatment of certain cases of MI. In a
meta-analysis including 20,006 patients, tiroﬁban was
signiﬁcantly more effective, than placebo at reducing the
risk of mortality (OR = 0.68; p = 0.001) or the composite
of death and MI (OR = 0.69; p< 0.001) at 30 days [7].
The INFUSE-AMI (Intracoronary Abciximab and Aspi-
ration Thrombectomy in Patients With Large Anterior
Fig. 1. Mean residual platelet reactivity at the time and 24 h after the
termination of tiroﬁban administration in patients receiving
combined antiplatelet therapy after PCI. Tiroﬁban effective-
ness was measured by TRAP, while clopidogrel efﬁciency
was monitored by ADP administration. ADP: adenosine
diphosphate, TRAP: thrombin receptor-activating peptide,
U: unit, *p< 0.00001
Table I Patient data
Baseline clinical characteristics (n = 37)
Age, mean± SD (years) 62.91± 8.92
Male gender, n (%) 22 (59.5)
Diabetes mellitus, n (%) 10 (27.0)
Arterial hypertension, n (%) 26 (70.2)
Dyslipidemia, n (%) 27 (73.0)
Smokers, n (%) 18 (48.6)
Prior PCI, n (%) 2 (5.4)
Prior coronary artery bypass graft, n (%) 3 (8.1)
Prior MI, n (%) 5 (13.5)
PCI procedure
Bare-metal stent, n (%) 31 (83.8)
Total stent length, mean± SD (mm) 44.0± 13.2
Stent count/patient, mean± SD (n) 2.1± 0.82
Laboratory ﬁndings 1 day after PCI
Hemoglobin (g/dl) 138.0± 15.0
Leukocyte count (g/l) 11.56± 3.3
Platelet count (g/l) 245.0± 48.0
Creatinine (μmol/l) 76.8± 30.0
High-sensitivity C-reactive protein (mg/l) 9.5± 19.5
Discharge medication
Aspirin, n (%) 37 (100.0)
Angiotensin-converting enzyme inhibitor/
angiotensin receptor blocker, n (%)
33 (89.2)
Beta blocker, n (%) 32 (86.5)
Proton pump inhibitor, n (%) 34 (91.9)
Statin, n (%) 36 (97.3)
ADP reactivity after tiroﬁban combination therapy
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MI) study also provides data strengthening the role of
GPIIb/IIIa inhibitors. In this trial, the infarct size at 30
days was smaller when the patients underwent both
thrombus aspiration and application of intracoronary
IIb/IIIa inhibitor abciximab, and larger if only thrombus
aspiration was performed (mean % of the left ventricle
14.7% vs. 18.6%, p = 0.03). The FABOLUS PRO (Facili-
tation through Aggrastat By drOpping or shortening
Infusion Line in patient with STEMI compared to or
on top of PRasugrel given at loading dOse) trial also
fortiﬁes the positive effect of GPIIb/IIIa antagonists:
tiroﬁban administered (as bolus only or bolus followed
by 2-h infusion) to patients withMI undergoing coronary
stenting together with either clopidogrel or prasugrel,
leads to a signiﬁcantly higher degree of platelet inhibition
compared with prasugrel alone [8, 9].
With the advent of new-generation ADP P2Y12 inhi-
bitors, the importance of GPIIb/IIIa receptor blockers
has been reduced in the adjunctive therapy of coronary
interventions. This is despite the fact that these drugs
were frequently applied in the major ACS trials of prasu-
grel and ticagrelor. Tiroﬁban was co-administered as
adjuvant in 54.4% of patients in the PLATO (A Study
of Platelet Inhibition and Patient Outcomes) trial and in
53.2% of patients in the TRITON-TIMI 38 (Trial to
Assess Improvement in Therapeutic Outcomes by Opti-
mizing Platelet Inhibition with Prasugrel–Thrombolysis
in MI 38) trial [10, 11].
Current recommendations based on 2014 ESC/
EACTS Guidelines on myocardial revascularization offer
the new-generation P2Y12 inhibitors for antiplatelet ther-
apy as the ﬁrst choice drugs in ACS. Although these drugs
are proven to have higher efﬁcacy, on the other hand, the
risk of bleeding is also increased [12].
Because of ﬁnancial limitations, clopidogrel is still the
most frequently used P2Y12 inhibitor in Hungary. Numer-
ous reports have found that the antiplatelet efﬁcacy of
clopidogrel exhibits considerable interindividual variability
[2, 13]. High platelet reactivity (HPR), also called as high
on-treatment platelet reactivity, during clopidogrel therapy
indicates persistent response of the P2Y12 receptor, which is
based on one measurement of on-treatment platelet reac-
tivity. Observational studies have demonstrated a strong
correlation between HPR and recurrent ischemic events in
stented patients [14, 15]. According to the results of a
meta-analysis (n = 9,187), patients with high on-clopido-
grel platelet reactivity after PCI, detected by an ADP-
speciﬁc laboratory assay, are at a higher risk for cardiovas-
cular death, non-fatal MI, ST, and recurrent ischemic
events, thus HPR considered as a strong predictor for
those after PCI [4]. Consequently, we can conclude that
PFT plays an important role in monitoring of clopidogrel
therapy after PCI; furthermore, HPR – detected by an
ADP-speciﬁc laboratory assay for 1 year – serves as the
condition of the reimbursement of prasugrel in Hungary.
ADP values measured during tiroﬁban activity were
signiﬁcantly lower than after elimination of the drug.
Since ADP-receptor blockers, including clopidogrel
selectively and irreversibly inhibit the P2Y12 purinorecep-
tor throughout the lifespan of the platelets. The differ-
ence is explained by the fact that the simultaneously
present GPIIb/IIIa inhibitor tiroﬁban inﬂuences the
efﬁcacy measurement of ADP receptor inhibitors. There-
fore, on the ﬁrst day, ADP values are artiﬁcially lower,
thus these laboratory results do not reﬂect the real
efﬁciency of ADP receptor inhibition and incorrectly
indicate a low risk for further thrombotic events. In
addition, because of the falsely measured clopidogrel
efﬁcacy, patients with an underlying insufﬁcient clopido-
grel reaction are excluded from reimbursed treatment
with prasugrel.
According to our data, elimination half-life (T1/2) of
tiroﬁban can be reliably calculated to be less than 2.5 h.
Twenty-four hours after the termination of tiroﬁban, the
drug is totally eliminated [ﬁve times T1/2 = 6.7 h (95%
CI: 1.75–11.6)]; thus, platelet GPIIb/IIIa receptors are
Fig. 2. Residual platelet reactivity in the function of the time after the termination of tiroﬁban administration in patients receiving combined
antiplatelet therapy. ADP: adenosine-diphosphate, TRAP: thrombin receptor-activating peptide, Kd: pharmacodynamic half time, Bmax:
maximal platelet reactivity
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released from inhibition. Inasmuch as the receptors’
function is regained and they are able to function, TRAP
values should raise – our data support the same conclu-
sion: increased TRAP values could be seen in Sample C.
The very ﬁrst time of ADP-receptor-speciﬁc efﬁciency
measurement showing adequate data should be obtained
at least 6.7 (95% CI: 1.75–11.6) h after the termination of
the GPIIb/IIIa inhibitors, practically after 12 h.
Examining the changes in residual platelet reactivity
after ADP stimulation, measured values correlate in par-
allel with the elimination of tiroﬁban. In addition, as the
GPIIb/IIIa inhibitor’s effect subsides, the variability
between individuals on clopidogrel treatment becomes
increasingly apparent – but these differences are masked
by the perioperative administration of tiroﬁban. As dem-
onstrated in Fig. 2A, two groups with adequate
and inadequate response separate to the 24 h time point.
Values above the curve belong to patients with HPR. On
the other hand, patients’ data under the curve demon-
strate normal post-treatment platelet reactivity (NPR).
Application of ADP receptor blocker clopidogrel is only
effective in the NPR group of patients. In contrast, in the
HPR group of patients (based on Hungarian and
European consensus recommendation for Multiplate
electrode aggregometry below 46 U), application of
clopidogrel is ineffective, thus adequate change in drug
therapy is advocated [5, 16].
Conclusion
We demonstrated that ADP-receptor-speciﬁc residual plate-
let reactivity is signiﬁcantly inﬂuenced by the presence of
concurrent GPIIb/IIIa inhibitor. Based on our results, in
cases of patients undergoing PCI and receiving combined
antiplatelet treatment, ADP-receptor-speciﬁc efﬁciency
measurements are valid only after the total elimination
of GPIIb/IIIa inhibitors. The ﬁrst measurement
should be obtained 12 h after the termination of the
GPIIb/IIIa inhibitors for valid results to be obtained. In
case of a need of an earlier measurement, methods other
than ADP-induced aggregation or development of algo-
rithm considering the total platelet reactivity and the time
elapsed from the cessation of GPIIb/IIIa infusion may be
required.
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